Bleichroeder LP’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bleichroeder LP’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,893,730	Closed	-$16.4M	–	90
2023 Q1	$16.4M	Hold	3,893,730	–	–	3.49%	8
2022 Q4	$23.4M	Sell	3,893,730 -50,000	-1%	-$273K	5.09%	5
2022 Q3	$23M	Sell	3,943,730 -5,000	-0.1%	-$31.2K	4.79%	6
2022 Q2	$23.6M	Buy	3,948,730 +89,023	+2%	+$456K	4.87%	6
2022 Q1	$18M	Buy	3,859,707 +3,609,707	+1,444%	+$10.8M	3.2%	7
2021 Q4	$620K	Buy	+250,000	New	+$612K	0.1%	59

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bleichroeder LP's CTIC Position: Q2 2023 in Review

Bleichroeder LP sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3,893,730 shares — an estimated $16.4M sold.

Bleichroeder LP first reported a position in CTIC in Q4 2021 and held it in 6 quarters. The position peaked at $23.6M in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Bleichroeder LP reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Bleichroeder LP sold 3,893,730 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $16.4M.
Bleichroeder LP first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 6 quarters.
Bleichroeder LP's CTI BioPharma Corp. (DE) Common Stock position peaked at $23.6M in Q2 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Bleichroeder LP's 13F filing for Q2 2023, filed 14 Aug 2023.